about
Aurones: a promising heterocyclic scaffold for the development of potent antileishmanial agents.Non-Biologic Nanodelivery Therapies for Rheumatoid Arthritis.Apo E-Functionalization of Solid Lipid Nanoparticles Enhances Brain Drug Delivery: Uptake Mechanism and Transport Pathways.Optimization of nanostructured lipid carriers loaded with methotrexate: A tool for inflammatory and cancer therapy.Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies.In vitro evaluation of bisnaphthalimidopropyl derivatives loaded into pegylated nanoparticles against Leishmania infantum protozoa.In vitro and in vivo anticancer activity of a novel nano-sized formulation based on self-assembling polymers against pancreatic cancer.In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells.Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype.Surface functionalization of polymeric nanospheres modulates macrophage activation: relevance in leishmaniasis therapy.Biodegradation of p-chlorophenol by a microalgae consortium.P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging.Synthesis and anti-parasitic activity of a novel quinolinone-chalcone series.Multiple Lipid Nanoparticles (MLN), a New Generation of Lipid Nanoparticles for Drug Delivery Systems: Lamivudine-MLN Experimental Design.Overcoming clofazimine intrinsic toxicity: statistical modelling and characterization of solid lipid nanoparticles.Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages.Biological evaluation of surface-modified magnetic nanoparticles as a platform for colon cancer cell theranostics.Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis.Development of PLGA nanoparticles loaded with clofazimine for oral delivery: Assessment of formulation variables and intestinal permeability.Sensitivity of P-glycoprotein tryptophan residues to benzodiazepines and ATP interaction.Crucial CD8(+) T-lymphocyte cytotoxic role in amphotericin B nanospheres efficacy against experimental visceral leishmaniasis.Development and validation of HPLC method with fluorometric detection for quantification of bisnaphthalimidopropyldiaminooctane in animal tissues following administration in polymeric nanoparticles.A method for functional mouse MDR3 P-glycoprotein reconstitution in Escherichia coli lipids.pH-sensitive nanoparticles for improved oral delivery of dapsone: risk assessment, design, optimization and characterizationApplication of pH-Responsive Fucoidan/Chitosan Nanoparticles to Improve Oral Quercetin DeliveryDelivering amoxicillin at the infection site - a rational design through lipid nanoparticlesChromatographic method for the simultaneous quantification of dapsone and clofazimine in nanoformulationspH-responsive chitosan based hydrogels affect the release of dapsone: Design, set-up, and physicochemical characterizationSwellable polymeric particles for the local delivery of budesonide in oral mucositisImproved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid NanoparticlesInsights on Ultrafiltration-Based Separation for the Purification and Quantification of Methotrexate in Nanocarriers
P50
Q34393660-CDF943D3-3461-47B0-9BB6-E87029970541Q38616625-B05669EF-5CFA-4A99-AC8F-5242962D6BECQ38709778-D5B1BE1B-6609-4C37-B880-813148CA33CAQ38853628-6427B4DB-9C83-44C1-B3CD-701A33711159Q39311884-F71F68C5-4110-4768-886B-9063C7AF88F8Q39383842-BA639F7D-819C-4B0E-B661-EA80D6151CEBQ39651416-C1E55775-54FE-4BE4-9109-1557DF86A7C2Q39653406-9CBA4728-FD28-4F4C-A485-D42A26F605FCQ40026075-7B7192F8-EEB3-4E37-A056-5157FEA9112DQ41468448-3429C2E6-C30F-428F-B6DA-81854936459FQ43368363-BCBFF8B9-8BAC-4303-B741-C2BDCCEE8779Q45344545-55AEC882-7D97-40E2-81E4-0B71272CD16BQ45370279-5C2D6838-2ACD-4861-A489-5F0CD39A0CB8Q48108849-714DF5D6-C552-4B19-A74E-71FFF483E78DQ50048230-D1A91478-768F-4D06-B06C-ED0B2C1B17B8Q50058428-B3562BDE-68AE-4067-A5A2-1DA50855873EQ50081211-012652E6-5758-4D59-B969-6F77108EE06BQ50084819-F8138102-7087-4726-96B2-303D0870E53DQ50084867-E4C95C3D-189A-49D4-AA51-373C9B3F719DQ50724502-289A2158-F509-401A-88C7-7A123FD6417FQ51759400-EAD5B6EC-15F5-4EE2-AF1B-6414BE42768AQ53213266-930142F5-C1A8-463D-AB86-A3AFCF3C3187Q53867391-39661C7A-3CE8-47AE-B541-E1FCE2B37186Q57570655-4BE2F3F5-7F1D-4A37-AC6C-7EC630A998D4Q61813614-437258BD-17BB-4125-834F-477850C9C2CDQ64097126-A9821F26-6B45-4CA7-9BE5-6CA84D67F3C5Q90158404-6273AA68-3031-4AC8-AFA5-5DAD3E7FA738Q91607402-F8F165EB-7217-4495-B405-90B8AA3256AEQ92296256-81C76A6D-7BEC-4A62-B319-3BDE67F02A92Q92959536-917816CA-30E5-4716-A55A-956B29D02006Q93184545-A24C5F1D-152E-4D1B-9509-03EF4D8ACA05
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sofia A Costa Lima
@ast
Sofia A Costa Lima
@en
Sofia A Costa Lima
@es
Sofia A Costa Lima
@nl
Sofia A Costa Lima
@sl
type
label
Sofia A Costa Lima
@ast
Sofia A Costa Lima
@en
Sofia A Costa Lima
@es
Sofia A Costa Lima
@nl
Sofia A Costa Lima
@sl
prefLabel
Sofia A Costa Lima
@ast
Sofia A Costa Lima
@en
Sofia A Costa Lima
@es
Sofia A Costa Lima
@nl
Sofia A Costa Lima
@sl
P106
P21
P31
P496
0000-0001-8777-5877